| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
216,097 | 167,457 | 81,206 | 56,514 | 41,618 | 15,446 | 4,306 |
Research and development costs paid to Amgen | ||||||
- | - | - | - | - | - | 553 |
General and administrative | ||||||
79,584 | 69,654 | 40,326 | 24,728 | 16,830 | 12,710 | 3,756 |
Total operating expenses | ||||||
295,681 | 237,111 | 121,532 | 81,242 | 58,448 | 28,156 | 8,615 |
Loss from operations | ||||||
-295,681 | -237,111 | -121,532 | -81,242 | -58,448 | -28,156 | -8,615 |
Interest and other income, net | ||||||
4,717 | 6,368 | 2,027 | 2,203 | 1,218 | 125 | 12 |
Loss before provision for income taxes | ||||||
-290,964 | -230,743 | -119,505 | -79,039 | -57,230 | -28,031 | -8,603 |
Provision for (benefit from) income taxes | ||||||
12 | -44 | -14 | 10 | -9 | -25 | 170 |
Net loss | ||||||
-290,976 | -230,699 | -119,491 | -79,049 | -57,221 | -28,006 | -8,773 |
Other comprehensive (loss) gain: | ||||||
Unrealized (loss) gain on available-for-sale securities | ||||||
560 | -189 | 32 | 335 | -418 | -100 | - |
Comprehensive loss | ||||||
-290,416 | -230,888 | -119,459 | -78,714 | -57,639 | -28,106 | -8,773 |
Net loss per common share: | ||||||
Basic and diluted net loss per common share | ||||||
-5.67 | -5.27 | -4.00 | -2.75 | -2.24 | -5.62 | -9.08 |
Weighted-average shares outstanding used to calculate basic and diluted net loss per common share | ||||||
51,308 | 43,811 | 29,863 | 28,732 | 25,583 | 4,986 | 965 |